^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Published date:
02/01/2022
Excerpt:
These data suggest the lack of benefit in the addition of ICI to chemotherapy in low PD-L1-expressing GEAC tumors...our analyses fail to demonstrate a survival advantage offered by the addition of ICIs to conventional chemotherapy in patients with low PD-L1–expressing tumors.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.21.01862
